Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They ...

The clinical-stage biopharmaceutical firm is pushing its NMDA platform while building a national network of psychiatric ...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, ...

NRx Pharmaceuticals has an Earnings ESP of -0.20% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Factors Shaping NRXP's Upcoming Results In ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a ...

Both have anticipated PDUFA dates prior to December 31, 2025 The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and distribute NRX-100 ...

NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed ...

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in a listen only mode. Following the presentation ...

NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and ...